Inactive Instrument

Analyst Reco. Amryt Pharma plc London S.E.

Equities

HC Wainwright Downgrades Amryt Pharma to Neutral From Buy, Cuts Price Target to $14.50 From $18	23-01-18	MT
Maxim Group Downgrades Amryt Pharma to Hold From Buy	23-01-10	MT
Cantor Fitzgerald Downgrades Amryt Pharma to Neutral From Overweight, Adjusts Price Target to $14.75 From $25	23-01-10	MT
Canaccord Genuity Downgrades Amryt Pharma to Hold From Buy, Adjusts Price Target to $17 From $19	23-01-10	MT
Rate Hike Clues, China Border Reopening Fuel Gains for US Equity Futures	23-01-09	MT
Canaccord Genuity Assumes Amryt Pharma at Buy Rating With $19 Price Target	22-09-06	MT
SVB Securities Adjusts Amryt Pharma's Price Target to $19 From $18, Keeps Outperform Rating	22-06-24	MT
SVB Leerink Adjusts Amryt Pharma's Price Target to $18 from $10, Keeps Outperform Rating	22-05-05	MT
SVB Leerink Adjusts Amryt Pharma's Price Target to $10 from $9, Keeps Outperform Rating	22-03-10	MT
HC Wainwright Adjusts Amryt Pharma's Price Target to $18 From $20, Maintains Buy Rating	22-03-10	MT
HC Wainwright Adjusts Amryt Pharma's Price Target to $20 From $29, Reiterates Buy Rating	22-03-01	MT

No results for this search